Table 2.
Characteristics of included child and adolescent studies.
| Country | Trauma sample | Pharmacotherapy | Timing after trauma | Comparator | n | PTSD/ASD outcome | Follow up | |
|---|---|---|---|---|---|---|---|---|
| Nugent* | USA | Injury | Propranolol | <12 h | Placebo | 20 | PTSD Incidence & Severity (CAPS-CA) | 6 weeks |
| Rosenberg et al.* | USA | Burns | Propranolol | <2 days | Standard therapy | 197 | PTSD Incidence (MAGIC) | 7 years |
| Robert et al.* | USA | Burns | Imipramine | 36 days | Chloral hydrate | 25 | ASD Severity (Clinical Interview) | 36 days |
*Included in meta-analysis, PTSD, post-traumatic stress disorder, ASD, acute stress disorder, n, number of participants included at final assessment,
CAPS-CA, clinician administered PTSD scale for children & adolescents, MAGIC, Missouri Assessment of Genetics Interview for Children,
PTSD Section, DICA, diagnostic interview for children & adolescents